Pancreatic islet amyloid formation in patients with noninsulin-dependent diabetes mellitus. Implication for therapeutic strategy.
Islet amyloid polypeptide (IAPP or amylin) is the main component of pancreatic islet amyloid found in the vast majority of patients with noninsulin-dependent (Type-2) diabetes mellitus (NIDDM). IAPP may also act as a hormone that antagonizes the effects of insulin on peripheral tissues, but the results with IAPP overproducing transgenic mice and other recent findings indicate that IAPP overproduction is unlikely to induce peripheral insulin resistance in NIDDM. However, IAPP may contribute to the progression of NIDDM by impairing beta-cell function via islet amyloid formation. This may be initiated by locally elevated IAPP concentrations, induced by insulin-resistance-associated beta-cell hyperactivity. In order to improve therapeutic results, we propose strategies to inhibit IAPP production and islet amyloid formation during the pathogenesis of NIDDM.
Oosterwijk
C
C
Department of Internal Medicine, Utrecht University Hospital, The Netherlands.
Höppener
J W
JW
van Hulst
K L
KL
Lips
C J
CJ
D000682:Amyloid / Q000096:biosynthesis* / Q000235:genetics; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D058228:Islet Amyloid Polypeptide; D051379:Mice; D008822:Mice, Transgenic
D000682:Amyloid; D058228:Islet Amyloid Polypeptide